Janssen Presents Longer-Term Data for TECVAYLI® (teclis

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today long-term data from the pivotal Phase 1/2 MajesTEC-1 study showing...

Related Keywords

Amsterdam , Noord Holland , Netherlands , Chicago , Illinois , United States , American , Rachel Kobos , Satu Glawe , Christie Corbett , Eastern Cooperative Oncology Group , Exchange Commission , None Of The Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , European Medicines Agency , Janssen Pharmaceutical Companies , European Commission , American Cancer Society , American Society Of Clinical Oncology , National Comprehensive Cancer Network , Janssen Research Development , Companies Of Johnson , International Myeloma Working Group , Janssen Oncology Research Development , Other Administration Reactions , Johnson , National Cancer Institute , Clinical Oncology , Annual Meeting , Confidence Interval , Not Evaluable , Amsterdam University Medical Centers , Suggest Durable Responses , Biweekly Dosing , Vice President , Janssen Oncology Research , Prophylactic Tocilizumab , Cytokine Release Syndrome , Lee Criteria , Independent Review Committee , Drug Administration , National Comprehensive Cancer , Risk Evaluation , Mitigation Strategy , Release Syndrome , Fetal Toxicity , Prescribing Information , Boxed Warning , Pharmaceutical Companies , Infectious Diseases , Janssen Research , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Long Term Follow Up From , Patients With , Refractory Multiple , American Society , Responses With Biweekly Dosing , Refractory Multiple Myeloma Achieving , Clinical Response , Participants With Relapsed , Refractory Multiple Myeloma , Accessed June , Escalation Study , Clinical Practice Guidelines , Comprehensive Cancer , Plasma Cell , Statistics About Multiple Myeloma , Janssen Oncology ,